Hippocampus-sparing volume-modulated arc therapy in patients with World Health Organization grade II glioma: a feasibility study
BackgroundRadiotherapy can improve the survival rates of patients with glioma; meanwhile, impaired cognitive functions have been brought to the forefront with the offending organ, the radiosensitive hippocampus. This study aimed to assess the feasibility of hippocampus-sparing volumetric-modulated a...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1445558/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832593921539047424 |
|---|---|
| author | Renxian Xie Renxian Xie Hongxin Huang Hongxin Huang Qingxin Cai Jiayang Lu Tong Chen Tong Chen Keyan Xie Jianzhou Chen Chuangzhen Chen |
| author_facet | Renxian Xie Renxian Xie Hongxin Huang Hongxin Huang Qingxin Cai Jiayang Lu Tong Chen Tong Chen Keyan Xie Jianzhou Chen Chuangzhen Chen |
| author_sort | Renxian Xie |
| collection | DOAJ |
| description | BackgroundRadiotherapy can improve the survival rates of patients with glioma; meanwhile, impaired cognitive functions have been brought to the forefront with the offending organ, the radiosensitive hippocampus. This study aimed to assess the feasibility of hippocampus-sparing volumetric-modulated arc therapy (HS VMAT) in patients with World Health Organization (WHO) grade II glioma.MethodsHS VMAT plans and non-hippocampus-sparing volumetric-modulated arc therapy (NHS VMAT) plans were generated using a computed tomography (CT) dataset of 10 patients who underwent postoperative radiotherapy. The dose volume histogram (DVH), homogeneity index (HI), conformity index (CI), and irradiated dose of the hippocampus and other organs at risk (OARs) were analyzed.ResultsNo significant differences were observed in HI and CI between the two plans. Regarding the protection of OARs, HS VMAT plans were equally capable and even lowered the radiation dosages to the brainstem (35.56 vs. 41.74 Gy, p = 0.017) and spinal cord (1.34 vs. 1.43 Gy, p = 0.006). Notably, HS VMAT plans markedly decreased doses to the ipsilateral hippocampus and the contralateral hippocampus, demonstrating its efficacy in hippocampal dose reduction.ConclusionThe HS VMAT plan can be used to efficiently lower the dosage delivered to the hippocampus and may, to some extent, help lessen the risk of cognitive damage. The encouraging results of our study need to be further validated by clinical trials to confirm the benefits of the HS VMAT plans in preserving cognitive functions in patients with glioma. |
| format | Article |
| id | doaj-art-452422cdfa644f77b26447df5af69efa |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-452422cdfa644f77b26447df5af69efa2025-01-20T07:19:58ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-01-011410.3389/fonc.2024.14455581445558Hippocampus-sparing volume-modulated arc therapy in patients with World Health Organization grade II glioma: a feasibility studyRenxian Xie0Renxian Xie1Hongxin Huang2Hongxin Huang3Qingxin Cai4Jiayang Lu5Tong Chen6Tong Chen7Keyan Xie8Jianzhou Chen9Chuangzhen Chen10Department of Radiation Oncology, Cancer Hospital of Shantou University Medical College, Shantou, ChinaShantou University Medical College, Shantou, ChinaDepartment of Radiation Oncology, Cancer Hospital of Shantou University Medical College, Shantou, ChinaShantou University Medical College, Shantou, ChinaDepartment of Radiation Oncology, Cancer Hospital of Shantou University Medical College, Shantou, ChinaDepartment of Radiation Oncology, Cancer Hospital of Shantou University Medical College, Shantou, ChinaDepartment of Radiation Oncology, Cancer Hospital of Shantou University Medical College, Shantou, ChinaShantou University Medical College, Shantou, ChinaShantou University Medical College, Shantou, ChinaDepartment of Radiation Oncology, Cancer Hospital of Shantou University Medical College, Shantou, ChinaDepartment of Radiation Oncology, Cancer Hospital of Shantou University Medical College, Shantou, ChinaBackgroundRadiotherapy can improve the survival rates of patients with glioma; meanwhile, impaired cognitive functions have been brought to the forefront with the offending organ, the radiosensitive hippocampus. This study aimed to assess the feasibility of hippocampus-sparing volumetric-modulated arc therapy (HS VMAT) in patients with World Health Organization (WHO) grade II glioma.MethodsHS VMAT plans and non-hippocampus-sparing volumetric-modulated arc therapy (NHS VMAT) plans were generated using a computed tomography (CT) dataset of 10 patients who underwent postoperative radiotherapy. The dose volume histogram (DVH), homogeneity index (HI), conformity index (CI), and irradiated dose of the hippocampus and other organs at risk (OARs) were analyzed.ResultsNo significant differences were observed in HI and CI between the two plans. Regarding the protection of OARs, HS VMAT plans were equally capable and even lowered the radiation dosages to the brainstem (35.56 vs. 41.74 Gy, p = 0.017) and spinal cord (1.34 vs. 1.43 Gy, p = 0.006). Notably, HS VMAT plans markedly decreased doses to the ipsilateral hippocampus and the contralateral hippocampus, demonstrating its efficacy in hippocampal dose reduction.ConclusionThe HS VMAT plan can be used to efficiently lower the dosage delivered to the hippocampus and may, to some extent, help lessen the risk of cognitive damage. The encouraging results of our study need to be further validated by clinical trials to confirm the benefits of the HS VMAT plans in preserving cognitive functions in patients with glioma.https://www.frontiersin.org/articles/10.3389/fonc.2024.1445558/fullhippocampus-sparingvolumetric-modulated arc therapygliomadosimetric feasibilityWorld Health Organization grade II |
| spellingShingle | Renxian Xie Renxian Xie Hongxin Huang Hongxin Huang Qingxin Cai Jiayang Lu Tong Chen Tong Chen Keyan Xie Jianzhou Chen Chuangzhen Chen Hippocampus-sparing volume-modulated arc therapy in patients with World Health Organization grade II glioma: a feasibility study Frontiers in Oncology hippocampus-sparing volumetric-modulated arc therapy glioma dosimetric feasibility World Health Organization grade II |
| title | Hippocampus-sparing volume-modulated arc therapy in patients with World Health Organization grade II glioma: a feasibility study |
| title_full | Hippocampus-sparing volume-modulated arc therapy in patients with World Health Organization grade II glioma: a feasibility study |
| title_fullStr | Hippocampus-sparing volume-modulated arc therapy in patients with World Health Organization grade II glioma: a feasibility study |
| title_full_unstemmed | Hippocampus-sparing volume-modulated arc therapy in patients with World Health Organization grade II glioma: a feasibility study |
| title_short | Hippocampus-sparing volume-modulated arc therapy in patients with World Health Organization grade II glioma: a feasibility study |
| title_sort | hippocampus sparing volume modulated arc therapy in patients with world health organization grade ii glioma a feasibility study |
| topic | hippocampus-sparing volumetric-modulated arc therapy glioma dosimetric feasibility World Health Organization grade II |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2024.1445558/full |
| work_keys_str_mv | AT renxianxie hippocampussparingvolumemodulatedarctherapyinpatientswithworldhealthorganizationgradeiigliomaafeasibilitystudy AT renxianxie hippocampussparingvolumemodulatedarctherapyinpatientswithworldhealthorganizationgradeiigliomaafeasibilitystudy AT hongxinhuang hippocampussparingvolumemodulatedarctherapyinpatientswithworldhealthorganizationgradeiigliomaafeasibilitystudy AT hongxinhuang hippocampussparingvolumemodulatedarctherapyinpatientswithworldhealthorganizationgradeiigliomaafeasibilitystudy AT qingxincai hippocampussparingvolumemodulatedarctherapyinpatientswithworldhealthorganizationgradeiigliomaafeasibilitystudy AT jiayanglu hippocampussparingvolumemodulatedarctherapyinpatientswithworldhealthorganizationgradeiigliomaafeasibilitystudy AT tongchen hippocampussparingvolumemodulatedarctherapyinpatientswithworldhealthorganizationgradeiigliomaafeasibilitystudy AT tongchen hippocampussparingvolumemodulatedarctherapyinpatientswithworldhealthorganizationgradeiigliomaafeasibilitystudy AT keyanxie hippocampussparingvolumemodulatedarctherapyinpatientswithworldhealthorganizationgradeiigliomaafeasibilitystudy AT jianzhouchen hippocampussparingvolumemodulatedarctherapyinpatientswithworldhealthorganizationgradeiigliomaafeasibilitystudy AT chuangzhenchen hippocampussparingvolumemodulatedarctherapyinpatientswithworldhealthorganizationgradeiigliomaafeasibilitystudy |